Previously recorded as Aurigene Discovery Technologies Limited (to 2022)
47 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2032
Next term end
21
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2038 · High confidence
Also notable
Ends Jan 2035 · High confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Oct 2038 · High confidence
Also notable
Ends Apr 2039 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends Oct 2032 · High confidence
Also notable
Ends Feb 2034 · High confidence
Dual Inhibitors of TIM-3 and PD-1 Pathways
US 11,497,734
Cited by 21 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors
US 9,732,095
Cited by 45 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
1,2,4-Oxadiazole Derivatives as Immunomodulators
US 10,590,093
Cited by 22 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Crystalline Forms of 3-Substituted 1,2,4- Oxadiazole
US 11,680,051
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Conjoint Therapies for Immunomodulation
US 11,497,735
Cited by 20 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
US 10,781,189
Cited by 29 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036.
Protein Kinase Inhibitors
US 9,447,091
The most cited patent in this portfolio, cited by 47 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2032.
Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
US 9,937,155
Cited by 11 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Crystalline Forms of 3-Substituted 1,2,4- Oxadiazole (US 11,680,051) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors (US 11,691,987) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Protein Kinase Inhibitors (US 10,391,082) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 2 fees due Jul 9, 2027
- 2 fees due Sep 17, 2027
- 2 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
- 2 of the patents on this record were granted since Aug 22, 2026
- 1 term has ended since Aug 22, 2026
- Sep 18 US 10,077,259 Bicyclic Heterocyclic Derivatives as Bromodomain Inhibitors · lapsed on the fee record
What they patent
The largest of its 21 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,447,091 | Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,391,082 | Protein Kinase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 9,630,932 | Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,937,155 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,080,740 | Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors In force · High confidence | In force | High confidence | |
| US 11,147,801 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 12,290,507 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,771,338 | 1,2,4-Oxadiazole Derivatives as Immunomodulators In force · High confidence | In force | High confidence | |
| US 10,173,989 | 1,2,4-Oxadiazole Derivatives as Immunomodulators In force · High confidence | In force | High confidence | |
| US 10,590,093 | 1,2,4-Oxadiazole Derivatives as Immunomodulators In force · High confidence | In force | High confidence |
Also on record, not counted in the 47: 1 patent in force now held by others · 5 patents ended · 32 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.